Carregando...
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells
HER2 amplification is found in >15% of gastric cancers (GC), and is associated with poor clinical outcome. Lapatinib, a dual HER2 and EGFR tyrosine kinase inhibitor, has shown promising in-vitro results in treating HER2+ cancer cells. However, several studies have shown that activation of alterna...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4209288/ https://ncbi.nlm.nih.gov/pubmed/22238368 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-11-0754 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|